[go: up one dir, main page]

MXPA02009895A - Proteinas de fusion de antigeno de nucleo de hepatitis b. - Google Patents

Proteinas de fusion de antigeno de nucleo de hepatitis b.

Info

Publication number
MXPA02009895A
MXPA02009895A MXPA02009895A MXPA02009895A MXPA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A MX PA02009895 A MXPA02009895 A MX PA02009895A
Authority
MX
Mexico
Prior art keywords
particles
loop
hbcag
sequences
core
Prior art date
Application number
MXPA02009895A
Other languages
English (en)
Inventor
David Rowlands
Original Assignee
Univ Leeds Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leeds Innovations Ltd filed Critical Univ Leeds Innovations Ltd
Publication of MXPA02009895A publication Critical patent/MXPA02009895A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/02—Hepadnaviridae, e.g. hepatitis B virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La capsida del virus de hepatitis B (HBV) se elabora de una especie individual de proteina llamada el antigeno de nucleo (HBcAg) que se auto-ensambla en particulas. Las particulas son altamente inmunogenicas y son capaces de presentar epitopes heterologos al sistema inmunitario cuando los epitopes se insertan en una region expuesta en la superficie de las particulas llamada la "asa el". Los bloques de construccion estructural de las particulas son dimeros estrechamente asociados de HBcAg en los cuales las asas el adyacentes estan yuxtapuestas de forma cercana. Se propone que las secuencias insertadas en la asa el, se restrinjan conformacionalmente en las particulas ensambladas cuando se presentan en la proteina de nucleo monomerica. La invencion busca solucionar este problema al enlazar covalentemente proteinas de nucleo como copias en tandem, por ejemplo, como dimeros, de modo que se pueden hacer inserciones independientes en cada copia. Esto es particularmente util para la insercion de grandes secuencias en la asa el, debido a que permite que estas secuencias se inserten en solo una copia de la proteina de nucleo por repeticion en tandem, reduciendo de este modo las potenciales oposiciones conformacionales en el ensamble. De manera alternativa, se puede insertar una secuencia diferente en cada asa el de una repeticion en tandem, incrementando de esta manera la flexibilidad de las particulas de HBcAg como un sistema de distribucion de epitopes.
MXPA02009895A 2000-04-07 2001-04-09 Proteinas de fusion de antigeno de nucleo de hepatitis b. MXPA02009895A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00107118 2000-04-07
PCT/GB2001/001607 WO2001077158A1 (en) 2000-04-07 2001-04-09 Hepatitis b core antigen fusion proteins

Publications (1)

Publication Number Publication Date
MXPA02009895A true MXPA02009895A (es) 2004-09-06

Family

ID=8168351

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009895A MXPA02009895A (es) 2000-04-07 2001-04-09 Proteinas de fusion de antigeno de nucleo de hepatitis b.

Country Status (18)

Country Link
US (1) US7270821B2 (es)
EP (1) EP1268530B1 (es)
JP (1) JP4713809B2 (es)
KR (1) KR100808313B1 (es)
CN (1) CN100360556C (es)
AP (1) AP1836A (es)
AT (1) ATE336502T1 (es)
AU (1) AU784345B2 (es)
BR (1) BR0109919A (es)
CA (1) CA2405438C (es)
DE (1) DE60122300T2 (es)
DK (1) DK1268530T3 (es)
EA (1) EA200201077A1 (es)
ES (1) ES2269371T3 (es)
MX (1) MXPA02009895A (es)
PT (1) PT1268530E (es)
WO (1) WO2001077158A1 (es)
ZA (1) ZA200208967B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511075A (ja) * 1999-10-08 2003-03-25 セルテック ファーマ ユアロップ リミテッド 免疫原の設計
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
JP4516748B2 (ja) 2001-09-14 2010-08-04 サイトス バイオテクノロジー アーゲー ウィルス様粒子中への免疫賦活物質のパッケージ化：調製法および使用法
KR100465643B1 (ko) * 2001-09-28 2005-01-13 (주) 에이프로젠 비형 간염 바이러스 프리에쓰1 항원 유래의 에피토프 태그및 이에 대한 항체를 이용한 폴리펩티드의 검출 및 정제방법
MXPA04002644A (es) 2001-10-05 2004-07-08 Cytos Biotechnology Ag Conjugados que portan un peptido de angiotensina y usos de los mismos.
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
NZ537003A (en) 2002-07-18 2008-03-28 Cytos Biotechnology Ag Hapten-carrier conjugates comprising virus like particles and uses thereof
NZ537688A (en) 2002-07-19 2007-01-26 Cytos Biotechnology Ag Vaccine compositions containing amyloid beta1-6 antigen arrays for treating and/or attenuating Alzheimer's disease
AU2004224762B2 (en) 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CN100537762C (zh) * 2004-06-24 2009-09-09 中国人民解放军军事医学科学院野战输血研究所 一种嵌合型病毒样颗粒疫苗载体蛋白及其制备方法与应用
KR100687653B1 (ko) * 2005-05-13 2007-02-27 유기현 스타-델타 결선용 전자개폐기의 제어방법
US20090214593A1 (en) * 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform
EP2865389A1 (en) 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
EP2459214A1 (en) 2009-07-30 2012-06-06 Pfizer Vaccines LLC Antigenic tau peptides and uses thereof
TR201808222T4 (tr) 2009-09-03 2018-07-23 Pfizer Vaccines Llc PCSK9 aşısı.
GB0918679D0 (en) * 2009-10-23 2009-12-09 Iqur Ltd Influenza vaccine
JP6199036B2 (ja) * 2010-03-16 2017-09-20 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ 自己タンパク質に対する体液性免疫応答に関わる腫瘍ワクチン接種
EP2575868A1 (en) 2010-06-07 2013-04-10 Pfizer Vaccines LLC Ige ch3 peptide vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CN102199217B (zh) * 2011-04-01 2013-03-27 中国人民解放军第三军医大学 乙型肝炎病毒多表位融合蛋白及其制备方法和应用
KR20140048119A (ko) 2011-04-15 2014-04-23 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 Ｄｎａ 백신
US10543261B2 (en) 2012-08-31 2020-01-28 Osaka University DNA vaccine containing VEGF-specific epitope and/or angiopoietin-2-specific epitope
CA2893120C (en) * 2012-12-11 2022-03-15 Imaxio Modified coiled coil type proteins having improved properties
JP2016528176A (ja) * 2013-06-06 2016-09-15 ジェイ ローランズ、デビッド シングルドメイン抗体ディスプレイ
CN104341506A (zh) * 2013-07-30 2015-02-11 复旦大学 一种重组融合蛋白及其用途
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
GB201402890D0 (en) 2014-02-18 2014-04-02 Iqur Ltd Vaccines based on hepatitis B Core antigens
GB201421692D0 (en) * 2014-12-05 2015-01-21 Iquar Ltd Vaccines based on hepatitis B core antigens
GB201505041D0 (en) * 2015-03-25 2015-05-06 Iqur Ltd Vaccines based on hepatitis B core antigens
WO2018089814A1 (en) 2016-11-11 2018-05-17 Fraunhofer Usa, Inc. Covalently fused viral coat proteins for the display of target molecules
CN119286871A (zh) 2018-04-19 2025-01-10 查美特制药公司 合成rig-i样受体激动剂
CN110343707B (zh) * 2019-05-30 2021-06-15 中国科学院生物物理研究所 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JP2514033B2 (ja) * 1987-05-20 1996-07-10 財団法人 癌研究会 Ｂ型肝炎ウィルスの複製を可能とする新規な培養細胞
NZ235315A (en) * 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
US5723129A (en) * 1991-10-16 1998-03-03 University Of Saskatchewan GnRH-leukotoxin chimeras
JPH06279500A (ja) * 1992-09-30 1994-10-04 Imuno Japan:Kk ＨＢｃ融合蛋白粒子およびその製造方法
WO1997035008A1 (en) * 1996-03-21 1997-09-25 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methods and compositions of chimeric polypeptides for tumor antigen vaccines
US20030021804A1 (en) * 1997-01-21 2003-01-30 Philip Needleman Immunological process for increasing the hdl cholestrol concentration
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US6180343B1 (en) * 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
JP2003511075A (ja) * 1999-10-08 2003-03-25 セルテック ファーマ ユアロップ リミテッド 免疫原の設計
CA2413546C (en) * 2000-06-22 2011-06-14 Celltech Pharmaceuticals Limited Modification of hepatitis b core antigen
US7351413B2 (en) * 2002-02-21 2008-04-01 Lorantis, Limited Stabilized HBc chimer particles as immunogens for chronic hepatitis

Also Published As

Publication number Publication date
AU784345B2 (en) 2006-03-16
CN1441807A (zh) 2003-09-10
CN100360556C (zh) 2008-01-09
KR100808313B1 (ko) 2008-02-27
BR0109919A (pt) 2003-03-11
KR20030009429A (ko) 2003-01-29
WO2001077158A1 (en) 2001-10-18
AU4670601A (en) 2001-10-23
DE60122300T2 (de) 2007-08-30
ZA200208967B (en) 2003-10-08
EP1268530B1 (en) 2006-08-16
JP4713809B2 (ja) 2011-06-29
US7270821B2 (en) 2007-09-18
DK1268530T3 (da) 2006-11-13
JP2003530123A (ja) 2003-10-14
EA200201077A1 (ru) 2003-04-24
PT1268530E (pt) 2006-12-29
ATE336502T1 (de) 2006-09-15
CA2405438A1 (en) 2001-10-18
DE60122300D1 (de) 2006-09-28
AP2002002658A0 (en) 2002-12-31
AP1836A (en) 2008-03-14
CA2405438C (en) 2011-07-12
ES2269371T3 (es) 2007-04-01
US20040223965A1 (en) 2004-11-11
EP1268530A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
MXPA02009895A (es) Proteinas de fusion de antigeno de nucleo de hepatitis b.
Netter et al. Antigenicity and immunogenicity of novel chimeric hepatitis B surface antigen particles with exposed hepatitis C virus epitopes
AU6616301A (en) Modification of hepatitis b core antigen
MX2009000650A (es) Vacunas para malaria.
CA2331846A1 (en) Expression vectors for stimulating an immune response and methods of using the same
NO20012760D0 (no) HBV kjerneantigenpartikler med multiple immunogene komponenter bundet via peptidligander
DK0414374T3 (da) Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf
MXPA05008677A (es) Particulas quimericas de hbc estabilizadas como vacuna terapeutica para hepatitis cronica.
CY1105600T1 (el) Κατασκευασματα νουκλεϊκων οξεων για γενετικη ανοσοποιηση
Bellier et al. Virus-like particle-based vaccines against hepatitis C virus infection
Riedl et al. Binding immune‐stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants
EP1013757A3 (en) Attenuated forms of bovine viral diarrhea virus
CN1874787B (zh) 预防/治疗hbv感染和hbv介导疾病的组合物
JP2003514576A5 (es)
ATE290399T1 (de) Hbv/hcv virus-ohnliche particle
Niedre‐Otomere et al. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre‐S1 antigens induce broadly reactive neutralizing antibodies
DE60115938D1 (de) Monoklonale antikörper gegen hepatitis b virus
KR920002629A (ko) B형 간염 코어 항원의 아미노산 잔기 서열
DE69334156D1 (de) Verfahren zur Reduzierung der Immunogenizität der variablen Regionen von Antikörpern
Ellis et al. Recombinant hepatitis B vaccines
Dreesman et al. Immunization of chimpanzees with hepatitis B virus-derived polypeptides
US20250197452A1 (en) Compositions and methods for treating and preventing hepatitis b and d
DE69814884D1 (de) Hepatitis b virale polypeptide
Kniskern et al. The application of molecular biology to the development of novel vaccines
Martineau et al. Expression of heterogonous peptides at two permissive sites of the MalE protein: antigen city and immunogenicity of foreign B-cell and T-cell epitomes

Legal Events

Date Code Title Description
FG Grant or registration